CORXEL Pharmaceuticals
The growth story
CORXEL Pharmaceuticals grew from 29 to 63 employees between 2021 and 2026, raising $452M along the way, most recently a Series D in January 2026.
About
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. Led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs), CORXEL's diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications.
Founders and leadership
Departments, and which ones grew
Headcount by function: Business Development 15 (+36% YoY), Research 9 (+29% YoY), Administrative 5 (+67% YoY), Human Resources 5 (0% YoY), Finance 4 (+33% YoY), Operations 4 (+100% YoY).
Talent flow
Most common previous employers of CORXEL Pharmaceuticals staff: Novartis (6), Novo Nordisk (6), Merck (4), Roche (4), Johnson & Johnson (3), Pfizer (3). Former CORXEL Pharmaceuticals employees most often moved to RTW Investments, LP (2), Tessera Therapeutics (1), XOMA Royalty (1), Hangzhou ZHONGMEI HUADONG Medicine Co. (1), LIDE Biotech (1), CSL (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at CORXEL Pharmaceuticals: Pharmaceutics (14), Clinical Development (13), Biotechnology (13), Life Sciences (13), Clinical Research (11), Clinical Trials (11), Management (11), Project Management (10).
Where the team actually sits
CORXEL Pharmaceuticals people are concentrated in Shanghai, China (16), Beijing, China (5), New York, United States (4), Capital Region of Denmark, Denmark (3). 3 offices on record.
Search footprint
CORXEL Pharmaceuticals attracts about 124 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 39 ranking keywords and lost 24 in the last period.
Frequently asked
CORXEL Pharmaceuticals has 63 employees as of September 2026.
CORXEL Pharmaceuticals has raised $452M in total, most recently a Series D round in January 2026.
The most common previous employers of current CORXEL Pharmaceuticals staff are Novartis (6 people), Novo Nordisk (6 people), Merck (4 people).
Former CORXEL Pharmaceuticals employees most often move to RTW Investments, LP (2), Tessera Therapeutics (1), XOMA Royalty (1).
CORXEL Pharmaceuticals attracts about 124 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among CORXEL Pharmaceuticals staff are Pharmaceutics, Clinical Development, Biotechnology, Life Sciences, Clinical Research.
CORXEL Pharmaceuticals staff are concentrated in Shanghai, China (16), Beijing, China (5), New York, United States (4).
CORXEL Pharmaceuticals has about 15 people in Business Development, up 36% over the past year, as of September 2026.
CORXEL Pharmaceuticals has about 9 people in Research, up 29% over the past year, as of September 2026.
Computed from 43 current and 19 former CORXEL Pharmaceuticals profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.